Skip to main content
. 2020 Sep 20;23(9):772–791. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2020.104.07

2.

各ICIs所致ir-AEs的总体发病率

The overall incidence of ir-AEs induced by ICIs

ICIs All-grade ir-AEs incidence (%)
(95%CI)
High-grade ir-AEs incidence (%)
(95%CI)
ir-AEs: immune-related adverse events; ICIs: immune checkpoint inhibitors.
PD-1 4.3 (2.6-7.0) 0.6 (0.3-1.1)
PD-L1 1.9 (0.7-4.9) 0.7 (0.5-0.9)
CTLA-4 5.2 (2.0-13.4) 2.1 (1.0-4.7)
PD-1+CTLA-4 12.2 (7.6-19.6) 4.9 (3.3-7.2)
Overall 5.1 (2.4-10.9) 1.4 (0.5-4.4)